Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors
Sponsor: Rongchang Pharmaceuticals Co., Ltd.
Summary
This study aims to evaluate the safety and efficacy of RCZY690 therapy in participants with advanced malignant solid tumors. Participants will receive RCZY690 monotherapy until the end of the study.
Official title: A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 Tablets in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
486
Start Date
2026-09-15
Completion Date
2029-08-15
Last Updated
2026-09-08
Healthy Volunteers
No
Conditions
Interventions
RCZY690 Tablets
Oral medication. The patient will continue treatment until unacceptable toxic reactions occur, the disease progresses, or any criteria for leaving the study are met.
RCZY690 tables
Oral medication. The patient will continue treatment until unacceptable toxic reactions occur, the disease progresses, or any criteria for leaving the study are met.
Locations (8)
Cancer Hospital, CAMS
Beijing, Beijing Municipality, China
Hunan Provincial Cancer Hospital
Hunan, Changsha, China
Zhejiang Cancer Hospital
Zhejiang, Hangzhou, China
Shandong Cancer Hospital
Shandong, Jinan, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Shanxi Provincial Cancer Hospital
Shanxi, Taiyuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China